在慢性活性抗体中介排斥中使用托西利祖马布:正在进行的随机受控开放多中心试验 (INTERCEPT研究) 的逻辑和协议

相关实验视频

Updated: Jun 30, 2025

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Lillian Streichart¹, Marie Felldin¹, Jana Ekberg¹

¹Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 413 45, Gothenburg, Sweden.

|March 23, 2024

概括

托西利祖马布可能为移植患者的慢性活性抗体中介排斥 (caAMR) 提供一种新疗法. 这项研究调查了它在长期保存移植功能和减少损伤方面的有效性.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
移植医学移植医学

背景情况:

慢性活性抗体中介排斥 (caAMR) 是长期移植失败的主要原因.
目前对caAMR的治疗方法有限,需要新的治疗策略.
托西利祖马布是一种IL-6受体抑制剂,具有治疗caAMR的潜力.

研究的目的:

评估托西利祖马布在治疗瘤检查证明的移植受体中的caAMR疗效.
评估托西利祖马布对减缓估计膜过率 (eGFR) 降低的影响.
调查托西利祖马布对移植组织学,抗体水平和患者报告结果的影响.

主要方法:

INTERCEPT研究是一项随机的,开放的,多中心的试验,涉及50名患有caAMR的脏移植接受者.
参与者被随机分配,接受托西利祖马布加标准护理 (SOC) 或单独接受SOC24个月.
主要终点是24个月的eGFR的斜率;次要终点包括iBox得分,DSA,组织学,蛋白尿,mGFR,存活率和患者报告的结果.

主要成果:

该部分尚未提供,因为研究仍在进行中.
需要进一步收集和分析数据来确定主要结果.
这项研究旨在提供关于托西利祖马布疗效和安全性的有力证据.

结论:

目前对于caAMR没有确定的治疗方法.
这项试验旨在为托西利祖马布作为对caAMR的新疗法提供证据.
托西利祖马布可能提供一种策略,以减缓长期的移植功能下降在移植接受者.

关键词:

慢性活性抗体中介排斥慢性活性抗体中介排斥提供者特异性抗体.互乐金-6是其中的一种.腎臟移植腎臟移植托西利兹马布的使用方法治疗方法治疗方法

更多相关视频

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...